Search results for: Angiotension
#33969492 2021/05/09 To Up
Risk Factors for Angiotension-Converting Enzyme Inhibitor-Associated Cough.
2543 related Products with: Risk Factors for Angiotension-Converting Enzyme Inhibitor-Associated Cough.100μg100μg100μg100μg100μg100ug100μg100 ug100ug96 wells (1 kit)100μg100 ug
No related Items
#33815099 2021/03/17 To Up
Activation of the Cholinergic Anti-inflammatory Pathway Attenuated Angiotension II-Dependent Hypertension and Renal Injury.: Angiotensin II (AngII) induces renal fibrosis, characterized by fibroblast proliferation, inflammatory cell infiltration and excessive extracellular matrix deposition, all of which was relevant closely to hypertension. The vagus nerve-related cholinergic anti-inflammatory pathway (CAP) modulates local and systemic inflammatory responses. The aim of present study was to determine the effect of CAP on renal inflammation and fibrosis. : AngII-induced hypertension was induced by 14-days low-dose AngII infusion from osmotic minipumps. We used GTS-21 dihydrochloride, a selective nicotinic acetylcholine receptor agonist. Daily intraperitoneal GTS-21 injection and/or vagotomy started after hypertension was confirmed and continued for 4Â weeks. The elevated blood pressure caused by AngII was significantly attenuated by GTS-21. Improved baroreflex sensitivity was observed after GTS-21 administration. Masson stain and immunoblotting revealed that deposition of excessive fibrosis and overexpression of inflammatory cytokines induced by AngII was reduced by GTS-21. To determine the role of autonomic control in CAP, unilateral vagotomy was performed. Vagotomy weakened the effect of CAP on AngII-induced hypertension. , GTS-21 suppressed NF-ÎºB activation, attenuated AngII-induced epithelial-mesenchymal transition and reduced inflammation and fibrosis in NRK-52E cells; Î±-bungarotoxin (Î±-Bgt, an Î±7-nAChR selective antagonist) partly inhibited these effects. CAP protected against AngII-induced hypertension via improvement in autonomic control, suppression of NF-ÎºB activation, and reduction of renal fibrosis and inflammatory response.
Shu-Jie Wu, Zhe-Wei Shi, Xue Wang, Fang-Fang Ren, Zuo-Yi Xie, Li Lei, Peng Chen
2125 related Products with: Activation of the Cholinergic Anti-inflammatory Pathway Attenuated Angiotension II-Dependent Hypertension and Renal Injury.100ug Lyophilized100ug Lyophilized100ug Lyophilized100μg100ug Lyophilized100ug Lyophilized1 ml100ug100μg100ug Lyophilized100ug Lyophilized
#33810568 2021/03/26 To Up
Synthesis and Characterization of a Minophosphonate Containing Chitosan Polymer Derivatives: Investigations of Cytotoxic Activity and in Silico Study of SARS-CoV-19.Chitosan is broadly used as a biological material since of its excellent biological activities. This work describes investigations of chitosan interaction with SARS-CoV-2, which is occupied by human respiratory epithelial cells through communication with the human angiotension-converting enzyme II (ACE2). The Î²-chitosan derivatives are synthesized and characterized by FT-IR, nuclear magnetic resonance (H and C NMR), mass spectrometry, X-ray diffraction, TGA, DSC, and elemental analysis. The Î²-chitosan derivatives were screened for cytotoxic activity against the HepG2 and MCF-7 (breast) cancer cell lines. Compound h (GI 0.02 ÂµM) is moderately active against the HepG2 cancer cell line, and Compound c is highly active (GI 0.01 ÂµM) against the MCF-7 cancer cell line. In addition, chitosan derivatives (a-j) docking against the SARS coronavirus are found by in-silico docking analysis. The findings show that compound c exhibits notable inhibition ability compared with other compounds, with a binding energy value of -7.9 kcal/mol. Based on the molecular docking results, the chitosan analog is proposed to be an alternative antiviral agent for SARS-CoV2.
Ponnusamy Packialakshmi, Perumal Gobinath, Daoud Ali, Saud Alarifi, Norah Salem Alsaiari, Akbar Idhayadhulla, Radhakrishnan Surendrakumar
2234 related Products with: Synthesis and Characterization of a Minophosphonate Containing Chitosan Polymer Derivatives: Investigations of Cytotoxic Activity and in Silico Study of SARS-CoV-19.1 ml1000 tests200 100ul200ul25 mg100 mg10 mg200ug10 mg48 assays 1 kit
#33802310 2021/03/03 To Up
Immunogenetic Predictors of Severe COVID-19.According to an analysis of published data, only 20% of patients with the new coronavirus infection develop severe life-threatening complications. Currently, there are no known biomarkers, the determination of which before the onset of the disease would allow assessing the likelihood of its severe course. The purpose of this literature review was to analyze possible genetic factors characterizing the immune response to the new coronavirus infection that could be associated with the expression of angiotension-converting enzyme 2 (ACE-2) and related proteins as predictors of severe Corona virus disease 2019 (COVID-19). We analyzed original articles published in Medline, PubMed and Scopus databases from December 2019 to November 2020. For searching articles, we used the following keywords: New coronavirus infection, Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), COVID-19, severe course, complications, thrombosis, cytokine storm, ACE-2, biomarkers. In total, 3714 publications were selected using the keywords, of which 8 were in congruence with all the criteria. The literature analysis of the association of immunogenic characteristics and the expression of ACE-2 and related proteins with the development of severe COVID-19 revealed following genetic factors: HLA-B*46:01 genotype, CXCR6 gene hypoexpression, CCR9 gene expression, TLR7, rs150892504 mutations in the ERAP2 gene, overexpression of wild-type ACE-2, TMPRSS2 and its different polymorphisms. Genes, associated with the severe course, are more common among men. According to the analysis data, it can be assumed that there are population differences. However, the diagnostic significance of the markers described must be confirmed with additional clinical studies.
Anna Malkova, Dmitriy Kudlay, Igor Kudryavtsev, Anna Starshinova, Piotr Yablonskiy, Yehuda Shoenfeld 5 G
#33618704 2021/02/22 To Up
Effect of Guanxin V in animal model of acute myocardial infarction.Acute myocardial infarction (AMI) is the most serious and lethal manifestation of coronary heart disease worldwide, presenting extremely high disability and mortality. Our previous studies have shown that Guanxin VÂ (GXV) could significantly improve the cardiac function and the blood flow dynamics, and reduce serum levels of inflammatory factors in AMI rats, thus triggering ventricular remodeling (VR) at post-AMI.
Xiaoxiao Zhang, Changle Shao, Songyi Cheng, Yao Zhu, Bo Liang, Ning Gu900 tests10 rxns10 10mg100 1 mL
Error loading info... Pleas try again later.
Error loading info... Pleas try again later.
#33416694 // To Up
Characteristics of Patients with Hypertension at a Nicaraguan Clinic.Describe the characteristics and pharmacological management of hypertensive patients in a Nicaraguan ambulatory care clinic.
Jennifer S Lee, Mark Humphrey, Morgan Adams, Myriam Torres, Timothy N Crawford, Jeff Hall100ul100ul100ug100ul100ug Lyophilized10reactions 100ug Lyophilized100μl100ul50 µg50 ug
No related Items
#33350197 // To Up
[Study on mechanism of Tibetan medicine Zuomua Decoction in treatment of hypertension based on network pharmacology and molecular docking technology].Hypertension is a kind of chronic cardiovascular system disease caused by a series of factors and carriers dysfunction, which belongs to the category of Tibetan medicine "Chalong disease", and has a high rate of disability and mortality. Zuomua Decoction is a classical Tibetan medicine for Chalong disease, but its mechanism is not clear. Therefore, in this paper we explored the multi-components, multi-targets and multi-channels mechanism of Zuomua Decoction in the treatment of hypertension based on network pharmacology and molecular docking technology. First of all, the chemical components of Zuomua Decoction were obtained in the retrieval of traditional Chinese medicine systems pharmacology database(TCMSP), China National Knowledge Infrastructure(CNKI) and Wanfang database. The potential targets of Zuomua Decoction were predicted by BATMAN-TCM database, and the targets of hypertension were obtained by using DisGeNET database. The intersection of these two targets set was taken to obtain the potential targets of Zuomua Decoction in the treatment of hypertension, and then the chemical compositions-targets network was constructed. Secondly, the intersection targets were imported into STRING database to obtain the interaction relationship of intersection targets, and the protein interaction network of Zuomua Decoction in the treatment of hypertension was constructed in Cytoscape. Topological, GO, and KEGG enrichment analysis were used to construct the key targets-signal pathways-biological processes network diagram and explore the mechanism of Zuomua Decoction in the treatment of hypertension. Finally, the key targets were selected to construct the pharmacodynamic identification models to verify the effect mode of Zomua Decoction in treating hypertension. The results showed that there were 61 chemical components and 90 potential targets in the compounds-targets network. We obtained 21 key targets, 154 signal pathways, and 382 biological processes in topological, GO, and KEGG enrichment analysis of the protein interaction network, and in the comprehensive analysis, it was found that Zuomua Decoction could reduce blood pressure by regulating renin angiotension aldosterone system, balancing the concentration of intracellular calcium and sodium ions and regulating vasoconstriction and relaxation. ACE, AGTR1, and ADRB2 were used as the carriers for molecular docking study on the components of Zuoma Decoction, and the results showed that the chemical components of Zuomua Decoction had a good binding activity with key targets. The purpose of this study is to provide ideas for the in-depth study of Zuoma Decoction in the treatment of hypertension, and provide scientific basis for its clinical rational application.
Gong Ba-Jia, Ren Yue, M A Jing, Geng Sang, Duo Jie-Ren-Qing, L I Gong-Yu, N I Ma-Ci-Ren, Zhang Yan-Ling
1090 related Products with: [Study on mechanism of Tibetan medicine Zuomua Decoction in treatment of hypertension based on network pharmacology and molecular docking technology].100ug5mg5mg50mg10mg10mg10mg0.2 mg5mg100.00 ug5mg5mg
#33276786 2020/12/04 To Up
Going beyond the mean: economic benefits of myocardial infarction secondary prevention.Using the example of secondary prophylaxis of myocardial infarction (MI), our aim was to establish a framework for assessing cost consequences of compliance with clinical guidelines; thereby taking cost trajectories and cost distributions into account.
Viktor von Wyl, Agne Ulyte, Wenjia Wei, Dragana Radovanovic, Oliver GrÃ¼bner, Beat BrÃ¼ngger, Caroline BÃ¤hler, Eva Blozik, Holger Dressel, Matthias Schwenkglenks
1644 related Products with: Going beyond the mean: economic benefits of myocardial infarction secondary prevention.1 mg100 IU100 0.1 mg 100 G11 mg500 Units100
No related Items
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia